Of note, a decrease in cholinergic signaling in individuals with duplication of CHRFAM7A, that encodes a dominant negative α7-nAChR inhibitor, is associated with IBD (Baird et al, 2016; Rueda Ruzafa et al, 2021). Here, CHRFAM7A is linked to inflammatory bowel disease.